Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
136-150 of 362

The Future of Oral SERDs: Combination Strategies
MinuteCE®The Future of Oral SERDs: Combination Strategies

Routes Reconsidered: A Case-Based Debate in SERD Selection
MinuteCE®Routes Reconsidered: A Case-Based Debate in SERD Selection

Spotlight on Asia-Pacific: Practice Beyond Borders
MinuteCE®Spotlight on Asia-Pacific: Practice Beyond Borders

Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
MinuteCE®Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap

Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
MinuteCE®Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
- advertisement

Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
MinuteCE®Beyond Fulvestrant: Oral SERDs Redefining ER Targeting

Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
MinuteCE®Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors

Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
- advertisement

Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer

Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
MinuteCE®Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates

Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms


























